MEDIA RELEASE – ECHO finds no substantial difference in HIV risk among DMPA-IM, copper IUD, and LNG implant usersWHO Statement on Depot-medroxyprogesterone acetate (DMPA)

A pivotal clinical trial to address a long-standing question about the relationship between hormonal contraceptive use and the risk of HIV acquisition has found no substantial difference in HIV risk among 7,829 African women who were randomly assigned to use one of three highly effective methods of contraception.